{
  "docId": "019de073-c7d4-73ef-8fef-22f9b5017668",
  "docSlug": "c95aa30aee69a466f8f903e1480a3b33",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 32 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 32,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "FA likely refers to Friedreich's Ataxia; FXN refers to frataxin protein.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-c7d4-73ef-8fef-22f9b5017668/8",
  "deckHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668",
  "deckJsonHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668.json",
  "deckAnchorHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Safety: CTI-1601 appears to be generally well tolerated at doses up to 100 mg administered daily for 13 days",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cff8168-eff2-4d1b-a79a-28c2c0cd093f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.56
      },
      "kind": "list",
      "text": "Pharmacokinetics: Pharmacokinetic analyses support evaluating a once-daily dosing regimen for CTI-1601",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ac6a6df-dc32-4cee-afaa-c217e8a9e925",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "list",
      "text": "Conclusion: Daily subcutaneous (SC) administration of 50mg and 100mg doses of CTI-1601 resulted in FXN levels in buccal cells that are at, or in excess of, those we would expect to see in phenotypically normal heterozygous carriers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4ca8769-cb5b-4a8f-9629-f8b4d5214d58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Pharmacodynamics: Daily dosing of CTI-1601 resulted in dose-dependent increases in FXN levels from baseline compared to placebo controls in all evaluated tissues",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c95798a8-adcb-41b4-9b82-5bda80ce25ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.4,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "POC: Proof-of-concept",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cedb4e75-be83-4794-928d-d60f42c2e483",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1 Top-line Data Demonstrated POC for CTI-1601 in FA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7bec210-0333-4fa5-a7b9-95c9919a1d89",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 8,
      "beatId": "8bf4cfad-4916-4c9e-af27-192a9a042ffa",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck highlights positive clinical trial results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 8,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "d0d0eba8-b767-4a62-beb5-07c937ed50af",
      "evidence": "The deck presents positive clinical trial results",
      "position": 2,
      "objective": "Demonstrate the efficacy of CTI-1601",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.8,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}